Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 12/20 | 0.47 |
| ▸ | DRD2 | P14416 | 11/20 | 0.47 |
| ▸ | HTR2A | P28223 | 8/20 | 0.47 |
| ▸ | HTR2C | P28335 | 8/20 | 0.47 |
| ▸ | HTR2B | P41595 | 8/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7681490 | 1.00 | HTR1A (0.47) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6630215 | 0.88 | HTR1A (0.40) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6631890 | 0.88 | HTR1A (0.40) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6628607 | 0.85 | HTR1A (0.40) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6630575 | 0.85 | HTR1A (0.40) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6196047 | 0.81 | DRD2 (0.43) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6631298 | 0.81 | DRD2 (0.43) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL4361994 | 0.81 | DRD2 (0.43) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6768901 | 0.79 | LMNA (0.37) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL7677439 | 0.79 | LMNA (0.37) | HTR1ADRD2HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6353002-B2 | DIOXINOINDOLE AND THIENOBENZODIOXIN COMPOUNDS WHICH ARE HT3 RECEPTOR ANTAGONISTS AND ARE USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 2002-03-05 | — | — | US | disclosed |
| US-20010008903-A1 | Therapeutic agents | BIRCH ALAN MARTIN (GB) | 2001-07-19 | — | — | US | disclosed |
| US-6201004-B1 | CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL, EATING, CARDIOVASCULAR, BRAIN, AND GASTROINTESTINAL DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 2001-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010008903-A1 | Therapeutic agents | GPR119, SNCA, HTR2B | HTR1A 5/4885DRD2 94/4885HTR2A 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.